Please reach out to Paula Cranmore (pcranmore@kumc.edu or 913-945-8870) for Exhibitor Application and/or W9.
Overview
The University of Kansas Cancer Center, Early Phase Program continues its efforts to collaborate with both basic science and clinical investigators and its partners in the industry to provide a unique way of exchanging scientific ideas and discuss opportunities to translate basic science discoveries into bedside care. This meeting is designed to build bridges for transformative conversations between laboratory and clinical researchers in academia and key leaders in the industry to identify areas of unmet needs towards eradicating cancer. This symposium will include a keynote presentation from a distinguished leader in cancer research and presentations from innovators in academia and industry with topics that include breast, lung, gastrointestinal, genitourinary, head and neck, skin, hematologic, gynecologic, pediatric malignancies, including rare tumors.
At the completion of this course, participants should be able to:
• Identify areas of opportunities for collaboration between leaders in academia in accelerating anticancer drug development using immunotherapy, targeted drugs and other novel therapies in colorectal, gastric esophageal, liver, bile duct, pancreatic, lung, head and neck, breast, prostate, bladder, kidney, soft tissue and bone sarcomas, hematologic malignancies including leukemia, lymphoma, multi myeloma, and other malignancies.
• Highlight ongoing efforts to narrow the gap in health disparities in our catchment area with special attention to our underserved rural population in gastrointestinal cancers, lung, genitourinary, breast, and hematologic, malignancies.
• Discuss new discoveries in drug development and ongoing efforts to identify molecular signatures that could be used as biomarkers in immunotherapy and targeted drugs to personalize cancer treatment in gastrointestinal, lung, genitourinary, breast, head and neck, sarcomas, hematologic, and other malignancies.
• Discuss evolving innovations in radiation therapy including those in combination with immunotherapy and novel targeted treatments in breast, lung, head and neck, gastrointestinal, genitourinary, sarcomas, hematologic and other malignancies.
Gives you: • Access into the symposium, exhibit at dinner reception and exhibit at symposium • 10 reps per table (with a larger table) • 10 rep access into symposium
Price:
$10,000.00
Gives you: • 2 rep per table • 4 rep access into symposium • 2 tables
$5,000.00
Gives you: • 2 rep per table • 2 rep access into symposium
$3,000.00